AstraZeneca pours more money into the Moderna pot

AstraZeneca ($AZN) has added an extra $140 million into the much-hyped early-stage mRNA biotech Moderna Therapeutics, adding to the company’s already huge VC cash pile of more than $1.2 billion.

This is according to Reuters, which said the two had extended their deal this week. Neither Astra nor Moderna however have released this publicly, and did not respond to requests from FierceBiotech about the upped stake.

The cash boost news comes just a few weeks after Moderna announced it would start the first trial under its existing collab with AstraZeneca. The Phase I study will test their experimental cardiometabolic drug AZD8601.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The biotech’s core tech is focused on using messenger RNA, or mRNA, to spur the production of human proteins within patient cells, creating what Moderna describes as an in vivo factory for targeted therapies.

AstraZeneca first signed up to a research pact with the biotech--a Fierce 15 company--back in 2013, and at the start of the year also saw the two pen another pact, this time on immuno-oncology mRNA therapeutics.

AstraZeneca is not the only one interested; Moderna has also gained much attention and R&D deals from Alexion ($ALXN), Merck ($MRK) and Vertex ($VRTX).

Reuters said that the new investment, part of a preferred-stock financing, lifted Astra’s stake in Moderna to 9%, up from its original investment three years ago.

- check out the Reuters story

Special Report: Moderna Therapeutics - 2013 Fierce 15

Related Articles:
Cash-rich Moderna to begin first AstraZeneca trial under collab deal
Much-hyped Moderna barrels into the clinic with 6 human trials planned for '16

Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.